DAPA-HF is the first outcomes trial with an SGLT2 inhibitor, Farxiga for treatment for patients with HFrEF HOPE for people living with heart failure has been presented on the 1st […]
DAPA-HF is the first outcomes trial with an SGLT2 inhibitor, Farxiga for treatment for patients with HFrEF HOPE for people living with heart failure has been presented on the 1st […]
Policies on our website
1.The content in this website should not replace and/or substitute the interactions with and advice you get from your healthcare professional, and if you have any concerns about your condition you should discuss these with your healthcare professional at the earliest opportunity.
2.This website uses cookies to improve your experience.